Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 3.7%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares fell 3.7% during mid-day trading on Monday . The company traded as low as $0.43 and last traded at $0.43. 29,671 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 93,100 shares. The stock had previously closed at $0.45.

Theriva Biologics Trading Down 3.7 %

The company has a market capitalization of $7.43 million, a price-to-earnings ratio of -0.38 and a beta of 1.45.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Theriva Biologics in the first quarter worth $133,000. Geode Capital Management LLC acquired a new position in shares of Theriva Biologics during the first quarter worth about $81,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Theriva Biologics in the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.